Replying to @F1
Max can do whatever he wants and the FIA just turns their head… but Lewis sneezes and it’s a penalty.
Chris Gibson
2,871 posts
Chris Gibson
@RecursionChris
Father/Husband/Scientist/Co-Founder & Chair $RXRX, “OG of TechBio,” Boards: @pacbio @cellinobio @sltrib @biohiveutah - TechBio/cars/musings/typos/opinions
- Huge day for Recursion and for neuroscience - so proud of our team for doing so many world firsts to achieve this and so excited to be working with the exceptional teams at Roche and Genentech to make great strides towards new neuro targets!Announcing the 1st #neuroscience phenomap – “Neuromap” – optioned under our collaboration with @Roche and @genentech for $30m. To build it, we produced over 1 trillion hiPSC-derived #neuronal cells – one of the largest such datasets – & scaled new genetic perturbation techniques.
- Each of us at @RecursionPharma have our own reasons for doing what we do. For some, it's a chance to take a swing at diseases that stole a loved one away from us too early. For others, it's the challenge of working on really hard problems with really smart people. And for others
- 1/ @Delta I am a big fan and fly you religiously, but something unfortunate happened today, and your 'contact us' page says to tweet you. So here goes. Before boarding my delayed flight to SF, I witnessed a women who didn't speak English confronted aggressively by the gate agent.
- Today, we are announcing a new pre-seed venture fund – Altitude Lab Fund – to support early-stage biotech startups facing the loss of SBIR grants due to recent federal funding policy shifts which have left many biotech founders in limbo. I wrote about why these funds are so
- I’m excited about the next stage of growth for @RecursionPharma as we become a public company - $RXRX! Our team has worked tirelessly to achieve this milestone and now it is time to put our heads down and get back to work on our mission! Thanks to all who have supported us!
- In a Large Language Model like @OpenAI's ChatGPT , a model has been trained to predict the best next token (e.g., word) to add iteratively in a written response. As these models get trained across more and more data, they start to learn foundational elements of text which, when
- Replying to @bradloncarTotally agree @bradloncar. Here are a few tips for those looking to partner with various TechBio companies who themselves don't have deep AI expertise to apply to diligence. 1) Look for groups who have significant representation from both bio/chem on their teams as well as
- When I finished my PhD and took a leave of absence from med school to start Recursion, I told my wife I thought the chances we would ‘make it’ were ~1%, but the impact would be so huge for patients if it worked that I had to try. Surreal to think back to day one now 3651 daysYesterday marked 10 years since our founding. We've come so far in our mission to decode biology, but we're just getting started.🚀 #drugdiscovery #techbio
00:00 - Announcing a $121M @RecursionPharma Series C to fund our mission to decode biology to radically improve lives. With pgms in clinic, discoveries in new areas (IO, Inflammation, etc), an amazing team, and a resupply complete, it's head-down execute time!
- H100s are in the @RecursionPharma house (undisclosed location) with our CTO @bmabey and team! This is what one of the world’s fastest supercomputers looks like when it comes off the truck. Kudos to our team and our partners at @nvidia for the fast work and great collaboration!
- Replying to @RecursionChrisAs I boarded, I was given a receipt by another agent saying miles had been deposited in my medallion account as a thank you for helping out. I'd like those miles removed.
- Today, 12 years to the day since founding @RecursionPharma, I am excited to share another bold move in pursuit of our audacious mission; I will be handing over the role of CEO of Recursion to our extraordinary Chief R&D and Commercial Officer Najat Khan as I move into the
- I am thrilled to announce that @RecursionPharma has entered into a definitive agreement to combine with @Exscientia – bringing together our high throughput target biology, foundation models & supercomputing w/ Exscientia’s generative #AI drug design & #chemistry #automation.We’re thrilled to announce that we’ve entered into a definitive agreement with @ExscientiaAI (Nasdaq: EXAI), combining our high throughput target biology w/ Exscientia’s generative #AI drug design and #chemistry #automation capabilities to industrialize drug discovery & deliver
